TITLE

Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes

AUTHOR(S)
Martis, S; Peter, I; Hulot, J-S; Kornreich, R; Desnick, R J; Scott, S A
PUB. DATE
August 2013
SOURCE
Pharmacogenomics Journal;Aug2013, Vol. 13 Issue 4, p369
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
To determine CYP2C19 and CYP2C8 allele frequencies, 28 coding and/or functional variants were genotyped in 1250 African-American, Asian, Caucasian, Hispanic and Ashkenazi Jewish (AJ) individuals. The combined CYP2C19 variant allele frequencies ranged from ∼0.30 to 0.41; however, the CYP2C8 frequencies were much lower (∼0.04-0.13). After incorporating previously reported CYP2C9 genotyping results from these populations (36 total CYP2C variants), 16 multi-ethnic CYP2C haplotypes were inferred with frequencies >0.5%. Notably, the 2C19*17-2C9*1-2C8*2 haplotype was identified among African-Americans (8%) and Hispanics (2%), indicating that CYP2C19*17 does not always tag a CYP2C haplotype that encodes efficient CYP2C-substrate metabolism. The 2C19*1-2C9*2-2C8*3 haplotype was identified in all populations except African-Americans and additional novel haplotypes were identified in selected populations (for example, 2C19*2-2C9*1-2C8*4 and 2C19*4B-2C9*1-2C8*1), together indicating that both CYP2C19*17 and *2 can be linked with other CYP2C loss-of-function alleles. These results have important implications for pharmacogenomic association studies involving the CYP2C locus and are clinically relevant when administering CYP2C-substrate medications.
ACCESSION #
89266918

 

Related Articles

  • Distribution of CYP2D6 polymorphism in the Middle Eastern region. Khalaj, Zahra; Baratieh, Zohreh; Nikpour, Parvaneh; Khanahmad, Hossein; Mokarian, Fariborz; Salehi, Rasoul; Salehi, Mansoor // Journal of Research in Medical Sciences;2019, Vol. 24, p1 

    Cytochrome P450 2D6 (CYP2D6) is an important drug metabolizing enzyme involved in the pharmacokinetic metabolism of drugs. CYP2D6 gene is highly polymorphic, and the combination of its different alleles yields different phenotypes including extensive metabolizer (EM), intermediate metabolizer...

  • Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update. Scott, S A; Sangkuhl, K; Stein, C M; Hulot, J‐S; Mega, J L; Roden, D M; Klein, T E; Sabatine, M S; Johnson, J A; Shuldiner, A R // Clinical Pharmacology & Therapeutics;Sep2013, Vol. 94 Issue 3, p317 

    Cytochrome P450 (CYP)2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 loss-of-function alleles impair formation of active metabolites, resulting in reduced platelet inhibition. In addition, CYP2C19 loss-of-function alleles confer increased risks for serious...

  • Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians. Kohlrausch, Fabiana; Carracedo, Ángel; Hutz, Mara // Molecular Biology Reports;Mar2014, Vol. 41 Issue 3, p1453 

    Potential causes of variability in drug response include intrinsic factors such as ethnicity and genetic differences in the expression of enzymes that metabolize drugs, such as those from Cytochrome P450 (CYPs) superfamily. Pharmacogenetic studies search for genetic differences between...

  • Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain. Llerena, A; Alvarez, M; Dorado, P; González, I; Peñas-LLedó, E; Pérez, B; Cobaleda, J; Calzadilla, L R // Pharmacogenomics Journal;Jun2014, Vol. 14 Issue 3, p229 

    The aims of this study were to evaluate the diclofenac metabolism in Hispanics from Cuba and Spain and its relation to ethnicity, CYP2C9 genotypes and environmental factors. Diclofenac hydroxylation capacity (concentration ratios of diclofenac/metabolites in 8-h urine) was studied in 160 Cuban...

  • Fatal intoxication cases: cytochromeP 4502D6 and 2C19 genotype distributions. Zackrisson, A.L.; Holmgren, P.; Gladh, A.B.; Ahlner, J.; Lindblom, B. // European Journal of Clinical Pharmacology;Oct2004, Vol. 60 Issue 8, p547 

    Objective: Many commonly used pharmaceuticals, such as antidepressants and neuroleptics as well as some illegal drugs, are metabolised by the cytochrome P 450 enzyme debrisoquine 4-hydroxylase (CYP2D6). Of Caucasians, 7-10% lack this enzyme, which can, upon administration of drugs in normal...

  • Global spread and genetic variants of the two CYP9M10 haplotype forms associated with insecticide resistance in Culex quinquefasciatus Say. Itokawa, K; Komagata, O; Kasai, S; Kawada, H; Mwatele, C; Dida, G O; Njenga, S M; Mwandawiro, C; Tomita, T // Heredity;Sep2013, Vol. 111 Issue 3, p216 

    Insecticide resistance develops as a genetic factor (allele) conferring lower susceptibility to insecticides proliferates within a target insect population under strong positive selection. Intriguingly, a resistance allele pre-existing in a population often bears a series of further adaptive...

  • Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards. Llarena, A.; Dorado, P.; O'Kirwan, F.; Jepson, R.; Licinio, J.; Wong, M.-L. // Pharmacogenomics Journal;2004, Vol. 4 Issue 6, p403 

    Interethnic differences in cytochrome P450 polymorphism might be responsible, at least in part, for the variations in drug disposition between ethnic groups. Of the various CYP2C9 alleles, CYP2C9*2 and CYP2C9*3 have been reported to have altered catalytic activities compared to the wild-type...

  • Pharmacogenetics of Phase I and Phase II Drug Metabolism. Crettol, Severine; Petrovic, Nenad; Murray, Michael // Current Pharmaceutical Design;1/11/2010, Vol. 16 Issue 2, p204 

    Genetic variation in the receptors and other intracellular targets that mediate the pharmacodynamic effects of drugs can affect therapeutic outcomes. However, at present greater knowledge is available concerning the extent of gene variation in drug metabolizing enzymes that determine drug...

  • Validation of incorporating flurbiprofen into the Pittsburgh cocktail*. Zgheib, Nathalie K.; Frye, Reginald F.; Tracy, Timothy S.; Romkes, Marjorie; Branch, Robert A. // Clinical Pharmacology & Therapeutics;Sep2006, Vol. 80 Issue 3, p257 

    Background: We have previously shown that flurbiprofen metabolism to 4′-hydroxyflurbiprofen provides an in vivo measure of cytochrome P450 (CYP) 2C9 activity. This study evaluated the possibility of incorporating flurbiprofen into the current 5-drug Pittsburgh cocktail.Methods: In a...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics